메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

UMED Wins CES Innovation Awards® 2026, Redefining Bladder Ca…

[ 메디채널 김갑성 기자 ] Transforming bladder care from hospital-centered procedures to accessible, data-driven digital urology SEOUL, South Korea, Dec. 4, 2025 -- UMED Inc, an AI-driven urology-focused healthcare startup, announced that its automated bladder irrigation system, UroRinse™ Light, has been named as a CES Innovation Awards® Honoree in the Digital Health category. UroRinse™ Light will be showcased at CES 2026 Eureka Park (Booth #62501-31). A Breakthrough Recognized on the Global Stage Hosted by the Consumer Technology Association (CTA), CES is the world's
- 김갑성 기자
- 2025-12-04 15:08
Menarini Asia-Pacific Expands Production Facilities, Strength…

Menarini announces the expansion of MiLab facilities in Cikarang, including a new warehouse and enhanced production facility to meet growing export demands. Another milestone includes the projected export of up to 700,000 units of Dermatix products to China alone this year. The event highlights Menarini's collaboration with the Indonesian government to position the country as a key regional pharmaceutical hub. JAKARTA, Indonesia, Dec. 4, 2025 -- Leading European biopharmaceutical company, Menarini Asia-Pacific ("Menarini"), announced the expansion of i
- 김갑성 기자
- 2025-12-04 14:30
AvernaとSphereaが組織構築に向けて提携、テストおよび品質エンジニアリングシ…

[ 메디채널 김갑성 기자 ] 両社が一体となり、テストおよび品質エンジニアリングソリューションの新たな世界標準を確立モントリオール、2025年12月4日 -- Avernaは、テストおよび品質ソリューションのグローバルリーダーとして、ミッションクリティカル産業向けテストシステムの著名なプロバイダーであるSphereaとの戦略的統合を発表します。この提携の下、SphereaがAvernaを完全に取得することとなり、両社が共有する「世界をリードするテストおよび品質エンジニアリングシステムインテグレーターになる」という使命において、大きな節目を迎えることになります。この取引は、国際的なプライベートエクイティファンドであるAndera Partnersによって支えられており、Walter Capital PartnersおよびAvernaとSpherea双方の経営陣による継続的な再投資も行われています。同取引は、規制当局の承認を前提として、2025年12月末までに完了する見通しです。 SphereaのCEOであるPatrice Bélie氏が、新たに形成されるSphereaグループのCEOとして指揮を執り、AvernaのCEOであるFrançois Rainville氏は引き続きAvernaの
- 김갑성 기자
- 2025-12-04 14:24
HiroPharmaConsulting (R) Granted Patent for AI-enabled Reliab…

OSAKA, Japan, Dec. 4, 2025 -- HiroPharmaConsulting (R) Co., Ltd. announced that it has received a patent for an innovative Good Pharmacovigilance Practice (GVP) Computerized System Validation (CSV) methodology designed to ensure the reliability of pharmacovigilance systems equipped with AI functions. This patent represents Japan's first intellectual property specifically dedicated to the reliability assurance of AI-enabled pharmacovigilance systems. The Japan Patent Office has officially recognized the invention's novelty and inventive step, underscoring its significance as a breakthrough in
- 김갑성 기자
- 2025-12-04 14:00
With Child Deaths Projected to Rise for the First Time This Cent…

[ 메디채널 김갑성 기자 ] New Goalkeepers Report models impact of global health funding cuts, offers roadmap of best buys and most effective investments to slow this reversal SEATTLE, Dec. 4, 2025 -- The number of children dying before their 5th birthday is projected to rise for the first time this century, reversing decades of global progress, according to new data published today in the Gates Foundation's 2025 Goalkeepers Report. In 2024, 4.6 million children died before their 5th birthday. According to modeling in the report, conducted by the Institute for Health Metrics and Evaluati
- 김갑성 기자
- 2025-12-04 13:01
Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI O…

CAMBRIDGE, Mass., Dec. 4, 2025 -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced the appointment of Dr. Hongjiang Miao as Chief AI Officer. Dr. Miao will be based in Shanghai and report directly to Dr. Di Hong, Chief Executive Officer of Nona Biosciences. In this role, Dr. Miao will lead the Nona AI team to advance the Company's A3 (Antibody engineering × AI × Automation) strategy a
- 김갑성 기자
- 2025-12-04 10:01
American Society of Clinical Oncology (ASCO) announces da…

[ 메디채널 김갑성 기자 ] Global oncology society calls for abstract submissions for research that is shaping the future of cancer care in advance of annual Asia-Pacific meeting in Singapore SINGAPORE, Dec. 4, 2025 -- The American Society of Clinical Oncology (ASCO) today launched its call for abstracts for its 2026 Breakthrough meeting, offering researchers globally the opportunity to present and discuss findings with an influential, international audience of cancer care professionals in the heart of Asia. In advance of the annual conference, held for the first-time in Singapore, oncol
- 김갑성 기자
- 2025-12-04 10:00
미국임상종양학회, 'ASCO 브레이크스루 2026' 개최 일정 발표

[ 메디채널 김갑성 기자 ] - 내년 싱가포르 열리는 '브레이크스루 학술대회' 위해 국내외 종양학 초록 연구 접수 개시 서울, 대한민국, 2025년 12월 4일 -- 미국임상종양학회(American Society of Clinical Oncology•ASCO)가 2026년 'ASCO 브레이크스루(ASCO Breakthrough)' 회의 개최 일정을 발표하고 이달 4일부터 초록 접수를 시작했다. 이번 회의는 아시아 핵심 허브인 싱가포르에서 처음으로 열리며 전 세계 연구자들이 국제 암 치료 전문가들과 교류하고 연구 성과를 발표•논의할 수 있는 기회를 제공한다. 초록 제출 기간은 2025년 12월 4일부터 2026년 2월 24일 오후 11시 59분(동부 표준시 기준)까지이며, 한국 시간으로는 2026년 2월 25일 오후 1시 59분까지 접수가 가능하다. 'ASCO 브레이크스루 2026'은 ASCO와 싱가포르 종양학회(Singapore Society of Oncology)가 아시아•태평양 지역의 협력 학회와 함께 공동 주최하며 2026년 6월 25일부터 27일까지 3일 간 개최된다. 이번 회의는 전 세계 종양학 전문가들이 최신 동향을
- 김갑성 기자
- 2025-12-04 10:00
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PR…

NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation ("CDE") of the National Medical Products Administration ("NMPA") of the PRC, with the proposed indication for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA) who have received at least one prior systemic treatment and FGFR inhibitor treatment. Previously, Tinengotinib has been granted B
- 김갑성 기자
- 2025-12-04 09:57
High Response in Bladder Cancer: Immvira Announced Its M…

SUZHOU, China, Dec. 4, 2025 -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical data (as of September 19, 2025) for its lead HSV-1 oncolytic virus product. MVR-T3011, in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. The patients were enrolled and treated with intravesical MVR-T3011 at two dose levels: 2x109 PFU and 1x1010 P
- 김갑성 기자
- 2025-12-04 08:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 18시 20분